Laparoscopic sleeve gastrectomy (LSG) as a stand alone procedure for the surgical management of morbid obesity represents 2% of the bariatric operations in the United States of America. In the USA, this technique was developed as a modification of the biliopancreatic diversion in 1988; and in the United Kingdom, the concept of LSG evolved as a modification of the Magenstrasse and Mill procedure.
Its acceptance as an alternative surgical treatment for obesity in the last years is due to the fact that it is a rapid and less traumatic operation and thus far is showing good resolution of co-morbidities and good weight loss. A further second surgical step is then easily feasible, if necessary.
An excessive weight loss (EWL) of 54 to 81% on average by 12 months have been reported (Himpens et al., 2006; Tucker et al., 2008), as well as the improvement in co-morbidities of obesity (2004 ASBS Consensus Conference on Surgery for Severe Obesity, 2005).